Sanford Zweifach

Sanford Zweifach joined Compugen’s Board of Directors in 2018. Mr. Zweifach is senior executive with over 25 years of experience in the life sciences industry. He has an extensive background in corporate partnering, business development, operations, private and public investing, and capital raising. Currently, Mr. Zweifach serves as a Venture Partner at Medicxi, an international investment firm focused on the life sciences sector. Previously, he founded and served as CEO of Nuvelution Pharma, Inc. and Ascendancy Healthcare, Inc. He was also a Partner at Reedland Capital Partners, a boutique investment bank, where he headed its life sciences M&A and advisory efforts. Prior to this, he was CEO of Pathways Diagnostics, a biomarker development company. Mr. Zweifach was a Managing Director/CFO of Bay City Capital, a venture capital/merchant banking firm, specializing in the biotech and the life science industry, where he was President of the firm’s M&A and financing division and was also responsible for oversight of the firm’s finance department. Prior to this, he was President and CFO of Epoch Biosciences, which was acquired by Nanogen. Currently, he is Chairman of the Board of Directors of Palladio Biosciences, an Executive Chairman of Janpix, Inc. and a member of the Board of Directors of IMIDomics, S.L. and Essa Pharma, Inc. Earlier in his career, Mr. Zweifach was a Certified Public Accountant (US) for Coopers & Lybrand and held various investment banking positions focusing on biotech. He received his B.A. in Biology from UC San Diego and an M.S. in Human Physiology from UC Davis.